In one paragraphArticle in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
6 authors.
Carly C TymmColumbia Center for Translational Immunology, Department of Medicine, Columbia University Medical Center, New York, NY 10032, USA.ORCID 0000-0003-2682-4051 Matthieu PaiolaColumbia Center for Translational Immunology, Department of Medicine, Columbia University Medical Center, New York, NY 10032, USA.ORCID 0000-0002-3536-861X Shoiab BukhariColumbia Center for Translational Immunology, Department of Medicine, Columbia University Medical Center, New York, NY 10032, USA.
Xizi HuColumbia Center for Translational Immunology, Department of Medicine, Columbia University Medical Center, New York, NY 10032, USA.ORCID 0009-0000-2192-6185 Robert WinchesterColumbia Center for Translational Immunology, Department of Medicine, Columbia University Medical Center, New York, NY 10032, USA.ORCID 0000-0002-7543-8037 Adam MorColumbia Center for Translational Immunology, Department of Medicine, Columbia University Medical Center, New York, NY 10032, USA.ORCID 0000-0002-2854-2405 Funding
Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Anil K Rustgi · 1985 to 2026
$115.3MClinical and Translational Science AwardUL1TR001873 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REILLY, MUREDACH P · 2016 to 2025
$99.0MNovel mechanisms regulating PD-1 signaling and functionR01AI125640 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Adam Mor · 2016 to 2026
$4.3MA systematic approach to uncover the basic mechanisms of checkpoint inhibitor immune related adverse eventsR01AI175498 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Adam Mor, Robert J Winchester · 2023 to 2026
$2.9MPAG is a novel target in immunotherapyR01AI150597 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MOR, ADAM · 2020 to 2024
$2.7MLeica Stellaris 8 Confocal MicroscopeS10OD032447 · OD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SNOECK, HANS-WILLEM E · 2022 to 2022
$652kBD Biosciences InfluxS10OD020056 · OD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SNOECK, HANS-WILLEM E · 2015 to 2015
$600kThe role of tissue-resident T cells in osteoarthritis during the transition to inflammatory arthritis induced by immune checkpoint inhibitorsR21AI197040 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Adam Mor, Robert J Winchester · 2026 to 2026
$452kFive-laser Aurora spectral flow cytometerS10OD030282 · OD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CREUSOT, REMI J · 2022 to 2022
$361kNCATS NIH HHS UL1 TR001873NCI NIH HHS P30 CA013696NIAID NIH HHS R01 AI125640NIAID NIH HHS R01 AI150597NIAID NIH HHS R01 AI175498NIAID NIH HHS R21 AI197040NIH HHS S10 OD020056NIH HHS S10 OD030282NIH HHS S10 OD032447
6 · The paper itselfAbstract
Immune checkpoint inhibitor (ICI) myocarditis is a rare but frequently fatal immune-related adverse event of cancer immunotherapy. Understanding the mechanisms of this toxicity is critical to balancing treatment with maintenance of antitumor immunity. Using integrated spatial and single-cell analyses in a pharmacological murine model, we identified regional infiltration of Ly6C
Indexed as
Immune Checkpoint InhibitorsMyocarditisMyocardiumTertiary Lymphoid StructuresAnimalsAntigens, LyCD8-Positive T-LymphocytesDisease Models, AnimalHumansLymphocyte ActivationMiceMonocytesProgrammed Cell Death 1 ReceptorAntigens, LyImmune Checkpoint InhibitorsLy-6C antigen, mouseProgrammed Cell Death 1 Receptor
Identifiers
PMID42647623
PMCPMC13510688
What OpenQuestion holds
Textmetadata
Read underepoch 390